Tags

Type your tag names separated by a space and hit enter

Current status of topical antiretroviral chemoprophylaxis.
Curr Opin HIV AIDS. 2012 Nov; 7(6):520-5.CO

Abstract

PURPOSE OF REVIEW

Recent studies suggest that the vaginal delivery of antiretroviral (ARV) agents - such as tenofovir, dapivirine and UC781 - may be a promising way to reduce the high rates of HIV infection among women in developing countries. This review examines these developments.

RECENT FINDINGS

The Microbicide Trials Network 003 study, a large phase IIb trial, was unable to show that daily dosing with 1% tenofovir vaginal gel was effective for HIV prevention. Nevertheless, preclinical and early-phase clinical trials suggest that ARV drugs - formulated in vaginal gels, rings, films, tablets and diaphragms - could be effective for HIV chemoprophylaxis.

SUMMARY

Investigations of topical chemoprophylaxis methods have seen mixed results in the past 12-18 months. Product adherence may prove to be one of the field's greatest challenges. Phase II and III trials continue to explore different dosing strategies for topical products that contain one or more ARV agents.

Authors+Show Affiliations

Department of Clinical Sciences, FHI 360, Washington DC, USA. LVanDamme@fhi360.orgNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22918449

Citation

Van Damme, Lut, and Michael Szpir. "Current Status of Topical Antiretroviral Chemoprophylaxis." Current Opinion in HIV and AIDS, vol. 7, no. 6, 2012, pp. 520-5.
Van Damme L, Szpir M. Current status of topical antiretroviral chemoprophylaxis. Curr Opin HIV AIDS. 2012;7(6):520-5.
Van Damme, L., & Szpir, M. (2012). Current status of topical antiretroviral chemoprophylaxis. Current Opinion in HIV and AIDS, 7(6), 520-5. https://doi.org/10.1097/COH.0b013e3283582ca7
Van Damme L, Szpir M. Current Status of Topical Antiretroviral Chemoprophylaxis. Curr Opin HIV AIDS. 2012;7(6):520-5. PubMed PMID: 22918449.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current status of topical antiretroviral chemoprophylaxis. AU - Van Damme,Lut, AU - Szpir,Michael, PY - 2012/8/25/entrez PY - 2012/8/25/pubmed PY - 2013/3/13/medline SP - 520 EP - 5 JF - Current opinion in HIV and AIDS JO - Curr Opin HIV AIDS VL - 7 IS - 6 N2 - PURPOSE OF REVIEW: Recent studies suggest that the vaginal delivery of antiretroviral (ARV) agents - such as tenofovir, dapivirine and UC781 - may be a promising way to reduce the high rates of HIV infection among women in developing countries. This review examines these developments. RECENT FINDINGS: The Microbicide Trials Network 003 study, a large phase IIb trial, was unable to show that daily dosing with 1% tenofovir vaginal gel was effective for HIV prevention. Nevertheless, preclinical and early-phase clinical trials suggest that ARV drugs - formulated in vaginal gels, rings, films, tablets and diaphragms - could be effective for HIV chemoprophylaxis. SUMMARY: Investigations of topical chemoprophylaxis methods have seen mixed results in the past 12-18 months. Product adherence may prove to be one of the field's greatest challenges. Phase II and III trials continue to explore different dosing strategies for topical products that contain one or more ARV agents. SN - 1746-6318 UR - https://www.unboundmedicine.com/medline/citation/22918449/Current_status_of_topical_antiretroviral_chemoprophylaxis_ L2 - https://doi.org/10.1097/COH.0b013e3283582ca7 DB - PRIME DP - Unbound Medicine ER -